Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intradermal Comirnaty BA.4-5 vaccination in adults with fibrodysplasia ossificans progressiva
NL-OMON53330Phase 2Recruiting
- Sponsor
- Vrije University Medical Center
- Start
- Jul 2023
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Comirnaty Bivalent Original/Omicron BA.4/BA.5 in coronavirus disease 2019 (COVID-19), sponsored by Vrije University Medical Center. Primary endpoints: Local reactogenicity, Systemic reactogenicity and tolerability and 1 more. Started Jul 2023; status: recruiting.
02
Drugs
Comirnaty Bivalent Original/Omicron BA.4/BA.5
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NL-OMON53330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53330.